ZYBERNO
Stock Report
Updated Aug 31, 2026

GENELUX CORPORATION (GNLX)

Healthcare • NASDAQ

$2.68

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
23.0/100
POOR BUSINESS
GENELUX CORPORATION (GNLX) scores 23/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-205.8%)
Debt-to-Equity (Solvency Risk):GOOD (0.30x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-171.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GENELUX CORPORATION (GNLX) stock report — Zyberno Score 23/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GNLX generated -$26.26M in Owner Earnings. Capital was deployed as follows: $1.99M invested in capital expenditures. Reinvestment rate: -3.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.68
Market Cap:$120.49M

Valuation Multiples (3)

P/B Ratio:7.48x
P/S Ratio:15,061.41x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$120.32M

Price Action & Momentum (1)

% of 52-Week High:31.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-138.8%
Reinvestment Rate:-3.1%
Fundamental Growth Rate (g):5.4%

Margin Analysis (1)

Ebitda Margin:-451,987.5%

Yield Metrics (2)

Earnings Yield:-$32.70
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.39x
Quick Ratio:2.39x
Cash Ratio:1.15x

Leverage Analysis (3)

Debt To Equity Ttm:0.30x
Debt-to-Equity Ratio:0.30x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:11,146,000.00
Cash And Cash Equivalents:9,184,000.00
Long Term Debt:$2.09M
Net Debt:-$172.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$8.00K
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$36.42M

Bottom Line Performance (3)

-$35.60M
Income Before Tax:$0.00
Ebitda Ttm:-36,159,000.00

Operating Expenses (5)

Operating Expenses:36,430,000.00
R And D Expense:22,681,000.00
Sga Expense:13,749,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-451,987.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$26.21M
Current Assets:$19.14M
Ppe Net:4,603,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:10,092,000.00
Current Liabilities:7,998,000.00
Long Term Debt:$2.09M
Short Term Debt:$6.92M

Equity & Capital (3)

Equity:$16.11M
Retained Earnings:-$301.94M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:6,918,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,273,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$25.89M-$27.88M

Investment Activities (2)

Investing Cash Flow:-$8.54M
Capital Expenditures Ttm:1,989,000.00

Financing Activities (3)

Financing Cash Flow:$18.54M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:18,525,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:263,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.86
-$0.86
Earnings Per Share Ttm:-$0.79

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.56

Book Value & Capital (2)

Book Value Per Share:$0.36
Cash Per Share:0.20

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:315,633.75
Cash Conversion Cycle:-317,631.75
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$26.26M

Damodaran Growth Analysis (2)

Reinvestment Rate:-3.1%
Fundamental Growth Rate (g):5.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):18.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:GNLX
Company Name:GENELUX CORPORATION
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:44.96M
Shares Outstanding Basic:44.96M
Shares Outstanding Diluted:44.96M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 14:10:57 UTC
Data Timestamp:2026-08-19T09:25:10.669209
Scroll to Top